With the recent announcement of the positive Phase 2b clinical study of XF-73 in the prevention of post-surgical staphylococcal infections, Destiny has become a rare UK biotech company owning two Phase 3-ready assets. Yet NTCD-M3 may have been forgotten by investors with the excitement surrounding the positive clinical trial announcement. Indeed, the recent IPO of a NASDAQ-listed company with a similar asset to M3 highlights not just Destiny’s superior asset quality, but also the valuation discr ....
04 May 2021
M3: another gem in the portfolio
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
M3: another gem in the portfolio
Destiny Pharma Plc (DEST:LON) | 17.5 -0.1 (-2.8%) | Mkt Cap: 16.7m
- Published:
04 May 2021 -
Author:
Hannah Crowe | Andy Smith -
Pages:
8
With the recent announcement of the positive Phase 2b clinical study of XF-73 in the prevention of post-surgical staphylococcal infections, Destiny has become a rare UK biotech company owning two Phase 3-ready assets. Yet NTCD-M3 may have been forgotten by investors with the excitement surrounding the positive clinical trial announcement. Indeed, the recent IPO of a NASDAQ-listed company with a similar asset to M3 highlights not just Destiny’s superior asset quality, but also the valuation discr ....